News | Patient Positioning Radiation Therapy | October 25, 2018

Brainlab Introduces ExacTrac Dynamic at ASTRO 2018

Radiotherapy patient positioning and monitoring technology now consolidates multiple spatial tracking technologies

Brainlab Introduces ExacTrac Dynamic at ASTRO 2018
Radiotherapy patient positioning and monitoring technology now consolidates multiple spatial tracking technologies

October 25, 2018 — Brainlab unveiled ExacTrac Dynamic at the American Society for Radiation Oncology (ASTRO) meeting, Oct. 21-24 in San Antonio, Texas. This concept for radiotherapy patient positioning and monitoring offers value on multiple fronts, including expanded clinical indications, broad technological advancements, enhanced user and patient experience, and technology consolidation. ExacTrac Dynamic is the next generation of ExacTrac X-Ray, Brainlab’s positioning and monitoring solution for radiotherapy treatments.

ExacTrac Dynamic addresses a full range of patient positioning and monitoring requirements that heretofore have been achieved, in most cases, by employing multiple systems combined with different internal tracking and surface scanning technologies. ExacTrac Dynamic is seamlessly integrated with a wide range of high-end linear accelerators and designed to deliver high-precision tracking and verification, while addressing the challenges associated with treating moving targets. All of these are critical requirements for delivering extremely effective and high doses in precision radiotherapy.

“We had the opportunity to be the first institution to enter into a strategic partnership for the development of ExacTrac Dynamic, as we were looking for a technology that could become the new standard for patient positioning and monitoring in Copenhagen,” commented Lars Dahl Allerup, new business development manager, corporate procurement, Capital Region of Denmark. “As a long standing partner of Brainlab, we have always been convinced of the superior performance of ExacTrac X-Ray for cranial treatments. What is important for us moving forward is to source technology like ExacTrac Dynamic that allows us to continue treating cranial indications but also take care of the larger patient population at the Herlev Hospital and Rigshospitalet, with a platform redesigned to monitor all external beam treatment indications.”

New high-speed surface tracking incorporates 300,000 3-D surface points to externally monitor patient position and detect movement during treatment. Each of the surface points acquired by the ExacTrac Dynamic structured light system are matched to a heat signal generated by a thermal camera, creating another dimension in which to track the patient’s position consistently and with great accuracy. The advanced surface tracking with ExacTrac Dynamic is not impacted by room lighting, reflections or skin tone, and has very low latency.

Internal motion caused by normal respiration must be addressed to ensure safe and effective treatments. In addition to external tracking, integrated X-ray monitoring with ExacTrac Dynamic verifies the patient’s position internally with real-time imaging, at any treatment position. The system offers ways to monitor clinical indications that are complicated by internal motion with additional workflows, such as deep inspiration breath hold and internal anatomy verification, providing confidence in true dose sparing of critical anatomy.

Customers will still take advantage of ExacTrac X-ray’s historical benefits, including high performance, non-coplanar capabilities and submillimetric precision. Cranial positioning and monitoring offers streamlined immobilization, non-coplanar imaging, Mu-triggered monitoring and gantry-angle triggered monitoring.

ExacTrac Dynamic simplifies frameless fixation with three moldable thermoplastic mask options designed with patient comfort in mind. Deep integration with linear accelerators from both Elekta and Varian Medical Systems allow positioning and monitoring workflows to function seamlessly, including automatic patient loading, gantry triggered imaging and automated beam-hold.

For more information: www.brainlab.com

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Professor David Sebag-Montefiore (Image courtesy of the University of Leeds)

Professor David Sebag-Montefiore (Image courtesy of the University of Leeds)

News | Radiation Therapy | April 07, 2020
April 7, 2020 — An intern...
Eclipse v16 has received CE mark and is 510(k) pending
News | Proton Therapy | April 06, 2020
April 6, 2020 — Driven by its Intelligent Cancer Care approach in developing new solutions that use advanced technolo
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
Women are more likely to be cured of cancer by radiotherapy but the side effects are worse.

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse. Image by Mark Kostich

News | Radiation Therapy | March 30, 2020
March 30, 2020 — Women undergoing radiotherapy for
A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Prostate Cancer | March 30, 2020
March 30, 2020 — In the wake of the COVID-19 pan
Novel scanners may open door for prognostic assessment in patients receiving cochlear implants

Iva Speck, MD, explains research showing that novel, fully digital, high-resolution positron emission tomography/computed tomography imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment. The research is featured in The Journal of Nuclear Medicine (read more at http://jnm.snmjournals.org/content/current). Video courtesy of Iva Speck, University Hospital Freiburg, Germany.

News | PET-CT | March 26, 2020
March 26, 2020 — Novel, fully digital, high-resolution...
 “Cyclotrons used in Nuclear Medicine Report & Directory, Edition 2020” that describes close to 1,500 medical cyclotrons worldwide
News | Nuclear Imaging | March 10, 2020
March 10, 2020 — MEDraysintell released its new and unique report “...
Accuray Incorporated announced that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife M6 System in Missouri at their state-of-the-art David C. Pratt Cancer Center
News | Stereotactic Body Radiation Therapy (SBRT) | February 27, 2020
February 27, 2020 — Accuray Incorporated announced that Mercy
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.